- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.12. | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | ||
| 11.12. | Cellectar lays off 60% of staff, ditches lead radiotherapy over FDA demand for another trial | ||
| 11.12. | Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt | ||
| 10.12. | In midstage colorectal cancer trial, Cardiff's KRAS candidate linked to 64% response rate at higher dose | ||
| 10.12. | Artivion nets FDA humanitarian green light for prosthetic aortic tear implant | ||
| 10.12. | Roche said it didn't want to buy Poseida last year: A look at how the $1.5B buyout came to be | ||
| 10.12. | FDA clears AngioDynamics' NanoKnife pulsed field ablation system for prostate cancer | ||
| 10.12. | Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup | ||
| 10.12. | BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer | ||
| 10.12. | NewAmsterdam's stock rises on early sign cholesterol drug improves cardiovascular outcomes | ||
| 10.12. | CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial | ||
| 10.12. | GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets | ||
| 10.12. | Health tech firm Carta Healthcare buys AI company that matches patients to cancer trials | ||
| 09.12. | Belharra's tide falls as the chemoproteomics biotech lays off 21 workers | ||
| 09.12. | Relmada turns to strategic options after scrapping 2 phase 3 trials | ||
| 09.12. | Gene therapy reduces seizures, improves cognitive and motor function in mice with severe epilepsy | ||
| 09.12. | Carisma axes sole clinical cell therapy candidate, lays off 23 workers | ||
| 09.12. | Cala Health raises $50M to spark growth of its wearable hand tremor therapy | ||
| 09.12. | Enanta's RSV antiviral reduces viral load in phase 2 pediatric study | ||
| 09.12. | AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing | ||
| 09.12. | Vivoryon's Alzheimer's asset suffers 2nd phase 2 fail, but hope as kidney drug remains | ||
| 09.12. | Merck ADC RORs into phase 3 with 100% complete response rate | ||
| 09.12. | BioAge's phase 2 obesity study derailed by liver side effects 2 months after IPO | ||
| 06.12. | Charles River Laboratories expands incubator to discovery-stage biotechs | ||
| 06.12. | AmplifyBio shutters South San Francisco site, lays off preclinical employees in Ohio |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
